Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05505162 · ClinicalTrials.gov registry record · Phase 1
Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05505162 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 24 participants.
The verdict
NCT05505162, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A study to assess the Pharmacokinetics (PK) of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy female participants of non-child-bearing potential, when administered alone and in combination with multiple oral doses of zibotentan.
Interventions
- DRUG EE/LNG
- DRUG Zibotentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05505162
The ClinicalTrials.gov registry entry for NCT05505162 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EE/LNG is the first listed.
NCT05505162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05505162 about?
NCT05505162 is a clinical study titled "Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.". A study to assess the Pharmacokinetics (PK) of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy female participants of non-child-bearing potential, when administered alone and in combination with multiple oral doses of zibotentan.
What is the current status of trial NCT05505162?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-08-24. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT05505162?
The interventions under investigation include: EE/LNG (DRUG), Zibotentan (DRUG).
Who is sponsoring clinical trial NCT05505162?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.